NCT06876506 Identification of B Regulatory Cells by Flow Cytometry
| NCT ID | NCT06876506 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hull University Teaching Hospitals NHS Trust |
| Condition | Pollen Allergy |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-01-21 |
| Primary Completion | 2027-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2026-01-21 with a primary completion date of 2027-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this laboratory and observational study is to develop a test to quantify B-regulatory cells in blood. This will be used to detect changes in B-regulatory cell populations in pollen and insect venom allergic patients who are receiving routine allergen immunotherapy treatment. The primary question this study aims to answer is; 1). Are changes in blood B-regulatory cells associated with successful allergen immunotherapy treatment, and therefore do these changes suggest patients have developed a suitable level of allergen tolerance and reduction in their allergic symptoms upon re-exposure to the causal allergen. Patients will also be asked to complete quality of life questionnaire periodically throughout the study to determine if there are associations between variation in B-regulatory cell populations in blood and allergic symptoms experienced.
Eligibility Criteria
Control cohort - Participants with: * No clinical and laboratory findings of IgE-mediated hypersensitivity (i.e. no clinical history of specific allergies to pollens, house dust mite or insect venoms * Negative serological testing for specific IgE to pollens, house dust mite and insect venoms * Patients aged 18 years or older Test cohort: * Participants over the age of 18 years * Participants with physician-diagnosed IgE-mediated allergic disease to pollens, house dust mite or insect venoms Exclusion Criteria: * Patients under the age of 18 years * Samples from patients with IgE-mediated allergic disease, treated or untreated, specific to allergens other than pollens, house dust mite and insect venom * Participants who are pregnant * Participants who cannot adequately understand verbal and / or written explanations given in English
Contact & Investigator
Kristina Emsell-Needham, BSc, MSc
PRINCIPAL INVESTIGATOR
Hull University Teaching Hospitals NHS Trust
Frequently Asked Questions
Who can join the NCT06876506 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pollen Allergy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06876506 currently recruiting?
Yes, NCT06876506 is actively recruiting participants. Contact the research team at Kristina.Emsell-Needham@nhs.net for enrollment information.
Where is the NCT06876506 trial being conducted?
This trial is being conducted at Hull, United Kingdom.
Who is sponsoring the NCT06876506 clinical trial?
NCT06876506 is sponsored by Hull University Teaching Hospitals NHS Trust. The principal investigator is Kristina Emsell-Needham, BSc, MSc at Hull University Teaching Hospitals NHS Trust. The trial plans to enroll 80 participants.